ORIC Pharmaceuticals, Inc.
NASDAQ:ORICBiotechnology
-$0.07 today
- Market cap
- $795.08M
- Beta
- 1.06
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$1.28
Volume 1.39M
Average 1.91M
ORIC Purchases of Investments
Cash used to buy marketable securities and other investments.
ORIC Pharmaceuticals, Inc.NASDAQ: ORIC
Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026
Purchases of investments grows, but more slowly than its trailing trend
Q1 FY2026 purchases of investments of $77.97M (cash outflow) rose 20.6% year over year, behind the +104.3% change in trailing-twelve-month purchases of investments. Sequentially, it rose 72.2% from the prior quarter. Over 3 fiscal years it compounded at +18.9% a year.
Context
- Purchases of investments grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +20.6% toward the trailing-twelve-month pace of +104.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (399.82M) USD
- Year-over-year change
- -58.7%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (399.82M) | -58.7% |
| FY2024 | 2024-12-31 | (251.92M) | -5.3% |
| FY2023 | 2023-12-31 | (239.24M) | -0.5% |
| FY2022 | 2022-12-31 | (238.12M) | -242.0% |
| FY2021 | 2021-12-31 | (69.63M) | — |
Purchases of Investments vs competitors
How ORIC compares with its peers on the latest reported figures
- ORIC's LTM Mar 2026 purchases of investments of $413.13M is the 3rd largest of the 11 companies compared; the peer median is $235.22M.
- Its year-over-year change of +104.3% is the 3rd highest of 9, against a peer median of +26.2%.
- Over three fiscal years its annual growth of +18.9% compares with a peer median of +15.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $747.49M | +53.2% | +133.7% | — | |
| LTM Mar 2026 | $446.68M | -32.7% | +33.8% | 2066.7% | |
| LTM Mar 2026 | $413.13M | +104.3% | +18.9% | — | |
| LTM Mar 2026 | $327.5M | +60.6% | — | — | |
| LTM Mar 2026 | $256.59M | -0.8% | — | — | |
| LTM Mar 2026 | $245.78M | +235.8% | +11.5% | — | |
| LTM Mar 2026 | $224.66M | -43.9% | -26.6% | 103.4% | |
| LTM Mar 2026 | $202.4M | +485.0% | +20.0% | 128.9% | |
| LTM Mar 2026 | $16.02M | — | — | 32.3% | |
| LTM Jun 2026 | $7.46M | -97.1% | -12.0% | 4.4% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ORIC) | $235.22M | +26.2% | +15.7% | 103.4% | |
Competitors are the stored peer set for ORIC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (78.72M) | (89.12M) | (100.7M) | (127.85M) | (129.47M) |
| Depreciation & Amortization | 897K | 966K | 1.03M | 1.11M | 1.22M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 12.85M | 14.46M | 15.23M | 20.21M | 0 |
| Change in Working Capital | 4.07M | (445K) | 4.9M | 1.97M | (5.46M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.93M | (1.48M) | 0 | 1.83M | (7.25M) |
| Other Working Capital | 1.14M | 1.03M | 4.9M | 143K | 1.79M |
| Other Non-Cash Items | 1.35M | (1M) | (6.15M) | (8.1M) | 20.34M |
| Operating Cash Flow | (59.54M) | (75.14M) | (85.69M) | (112.66M) | (113.37M) |
| Capital Expenditures | (939K) | (2.08M) | (849K) | (1.19M) | (712K) |
| Acquisitions (Net) | 1.38M | 2.08M | 0 | 0 | 0 |
| Purchases of Investments | (69.63M) | (238.12M) | (239.24M) | (251.92M) | (399.82M) |
| Sales of Investments | 229M | 130.95M | 196.69M | 275.25M | 252.5M |
| Other Investing Activities | (1.38M) | (2.08M) | 0 | 0 | 0 |
| Investing Cash Flow | 158.44M | (109.25M) | (43.4M) | 22.14M | (148.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 50M | 25M | 85M | 125M | 247.66M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (866K) | 225K | 658K | 1.55M | 0 |
| Financing Cash Flow | 49.13M | 25.23M | 85.66M | 126.55M | 247.66M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 148.03M | (159.17M) | (43.43M) | 36.02M | (13.74M) |
| Free Cash Flow | (60.48M) | (77.22M) | (86.54M) | (113.85M) | (114.08M) |
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
Intrinsic Alpha fair value
Locked
Current Price
$7.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.